322 related articles for article (PubMed ID: 29439836)
1. Hospital variation and the impact of postoperative complications on the use of perioperative chemo(radio)therapy in resectable gastric cancer. Results from the Dutch Upper GI Cancer Audit.
Schouwenburg MG; Busweiler LAD; Beck N; Henneman D; Amodio S; van Berge Henegouwen MI; Cats A; van Hillegersberg R; van Sandick JW; Wijnhoven BPL; Wouters MWJ; Nieuwenhuijzen GAP;
Eur J Surg Oncol; 2018 Apr; 44(4):532-538. PubMed ID: 29439836
[TBL] [Abstract][Full Text] [Related]
2. Factors contributing to variation in the use of multimodality treatment in patients with gastric cancer: A Dutch population based study.
Beck N; Busweiler LAD; Schouwenburg MG; Fiocco M; Cats A; Voncken FEM; Wijnhoven BPL; van Berge Henegouwen MI; Wouters MWJM; van Sandick JW;
Eur J Surg Oncol; 2018 Feb; 44(2):260-267. PubMed ID: 29273212
[TBL] [Abstract][Full Text] [Related]
3. Trends in the use of evidence-based therapy for resectable gastric cancer.
Snyder RA; Penson DF; Ni S; Koyama T; Merchant NB
J Surg Oncol; 2014 Sep; 110(3):285-90. PubMed ID: 24891231
[TBL] [Abstract][Full Text] [Related]
4. Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy.
Kim Y; Squires MH; Poultsides GA; Fields RC; Weber SM; Votanopoulos KI; Kooby DA; Worhunsky DJ; Jin LX; Hawkins WG; Acher AW; Cho CS; Saunders N; Levine EA; Schmidt CR; Maithel SK; Pawlik TM
Surgery; 2017 Aug; 162(2):285-294. PubMed ID: 28578142
[TBL] [Abstract][Full Text] [Related]
5. Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients.
Fitzgerald TL; Efird JT; Bellamy N; Russo SM; Jindal C; Mosquera C; Holliday EG; Biswas T
Cancer; 2017 Aug; 123(15):2909-2917. PubMed ID: 28386965
[TBL] [Abstract][Full Text] [Related]
6. Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial.
Claassen YHM; Hartgrink HH; Dikken JL; de Steur WO; van Sandick JW; van Grieken NCT; Cats A; Trip AK; Jansen EPM; Meershoek-Klein Kranenbarg WM; Braak JPBM; Putter H; van Berge Henegouwen MI; Verheij M; van de Velde CJH
Eur J Surg Oncol; 2018 May; 44(5):613-619. PubMed ID: 29503129
[TBL] [Abstract][Full Text] [Related]
7. International benchmarking in oesophageal and gastric cancer surgery.
Busweiler LAD; Jeremiasen M; Wijnhoven BPL; Lindblad M; Lundell L; van de Velde CJH; Tollenaar RAEM; Wouters MWJM; van Sandick JW; Johansson J; Dikken JL
BJS Open; 2019 Feb; 3(1):62-73. PubMed ID: 30734017
[TBL] [Abstract][Full Text] [Related]
8. Trends in the use and impact of neoadjuvant chemotherapy on perioperative outcomes for resected gastric cancer: Evidence from the American College of Surgeons National Cancer Database.
Greenleaf EK; Hollenbeak CS; Wong J
Surgery; 2016 Apr; 159(4):1099-112. PubMed ID: 26704785
[TBL] [Abstract][Full Text] [Related]
9. Treatment trends and predictors of adjuvant and neoadjuvant therapy for gastric adenocarcinoma in the United States.
Sherman KL; Merkow RP; Bilimoria KY; Wang CE; Mulcahy MF; Benson AB; Bentrem DJ
Ann Surg Oncol; 2013 Feb; 20(2):362-70. PubMed ID: 22890592
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant chemo radiotherapy after gastrectomy and D2 lymphadenectomy in patients with gastric cancer in the National Institute of Cancer, Lima, Peru].
Montenegro P; Flores L; Quintana S; Casanova L; Ruíz E; León J; Mantilla R
Rev Gastroenterol Peru; 2013; 33(1):34-8. PubMed ID: 23539054
[TBL] [Abstract][Full Text] [Related]
11. Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity after Gastrectomy for Gastric Cancer.
Téoule P; Trojan J; Bechstein W; Woeste G
Dig Surg; 2015; 32(4):229-37. PubMed ID: 25966823
[TBL] [Abstract][Full Text] [Related]
12. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
[TBL] [Abstract][Full Text] [Related]
13. High-Grade Toxicity to Neoadjuvant Treatment for Upper Gastrointestinal Carcinomas: What is the Impact on Perioperative and Oncologic Outcomes?
Robb WB; Messager M; Gronnier C; Tessier W; Hec F; Piessen G; Mariette C;
Ann Surg Oncol; 2015 Oct; 22(11):3632-9. PubMed ID: 25676845
[TBL] [Abstract][Full Text] [Related]
14. National Trends in Multimodality Therapy for Locally Advanced Gastric Cancer.
Sada YH; Smaglo BG; Tran Cao HS; Mok H; Musher BL; Massarweh NN
J Surg Res; 2019 May; 237():41-49. PubMed ID: 30694790
[TBL] [Abstract][Full Text] [Related]
15. Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer Collaborative.
Jin LX; Sanford DE; Squires MH; Moses LE; Yan Y; Poultsides GA; Votanopoulos KI; Weber SM; Bloomston M; Pawlik TM; Hawkins WG; Linehan DC; Schmidt C; Worhunsky DJ; Acher AW; Cardona K; Cho CS; Kooby DA; Levine EA; Winslow E; Saunders N; Spolverato G; Colditz GA; Maithel SK; Fields RC
Ann Surg Oncol; 2016 Aug; 23(8):2398-408. PubMed ID: 27006126
[TBL] [Abstract][Full Text] [Related]
16. Adoption of evidence-based novel therapies in the treatment of gastric cancer: A national observational study.
Mokdad AA; Ali A; Yopp AC; Polanco PM; Nassour I; Mansour JC; Choti MA; Minter RM; Wang SC; Porembka MR
Cancer; 2018 Mar; 124(6):1122-1131. PubMed ID: 29211302
[TBL] [Abstract][Full Text] [Related]
17. Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study.
Mokadem I; Dijksterhuis WPM; van Putten M; Heuthorst L; de Vos-Geelen JM; Haj Mohammad N; Nieuwenhuijzen GAP; van Laarhoven HWM; Verhoeven RHA
Gastric Cancer; 2019 Nov; 22(6):1263-1273. PubMed ID: 30949777
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Chemoradiotherapy for Non-Pretreated Gastric Cancer.
Ho VKY; Jansen EPM; Wijnhoven BPL; Neelis KJ; van Sandick JW; Verhoeven RHA; Lemmens VEP; van Laarhoven HWM
Ann Surg Oncol; 2017 Nov; 24(12):3647-3657. PubMed ID: 28831737
[TBL] [Abstract][Full Text] [Related]
19. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis.
Kumagai K; Rouvelas I; Tsai JA; Mariosa D; Lind PA; Lindblad M; Ye W; Lundell L; Schuhmacher C; Mauer M; Burmeister BH; Thomas JM; Stahl M; Nilsson M
Eur J Surg Oncol; 2015 Mar; 41(3):282-94. PubMed ID: 25491892
[TBL] [Abstract][Full Text] [Related]
20. Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radio-chemo-therapy.
Kucukoner M; Arpaci E; Isikdogan A; Bilici M; Uncu D; Cetin B; Dane F; Inanc M; Ekinci AS; Inal A; Cayir K; Yetisyigit T; Ozdemir N; Kaplan MA; Aksoy S; Alkıs N; Tekin SB; Eroglu C; Turhal S; Buyukberber S
Neoplasma; 2013; 60(1):19-25. PubMed ID: 23067212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
